Ann: Appendix 4C, page-40

  1. 6,848 Posts.
    lightbulb Created with Sketch. 2210
    For this type of company at the point where it is... that is, it has the approvals required in place, was not seeking money for highly uncertain clinical trials/proof of concept but money to get boots on the ground and build up inventory needed to sell. I have to disagree and think retail holders can make a meaningful contribution to funding.

    Just look at PNV. Raised 7 million in a placement and 16 million in a SPP. A couple of months later the sp has doubled. Although they are obviously selling a different product but they are roughly at the same stage and looking to ramp up sales.

    If they are raising for clinical trials etc fair enough, leave the retail holders out. Too much uncertainty there. But not when you are just gearing up for sales.
    Last edited by Sojourner: 16/02/18
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.1¢
Change
0.000(0.00%)
Mkt cap ! $6.684M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
8 10088767 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 83302138 41
View Market Depth
Last trade - 16.21pm 30/07/2025 (20 minute delay) ?
AXP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.